SCHEMBL361480

SCHEMBL361480

NCCCCCCC(N)C(N)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.64
▸ GNAI3 P08754 1/20 0.49
▸ GNAO1 P09471 1/20 0.49
▸ GNAI1 P63096 1/20 0.49
▸ CPB2 Q96IY4 2/20 0.45
▸ RNPEP Q9H4A4 1/20 0.45
▸ DPP7 Q9UHL4 8/20 0.43
▸ DPP8 Q6V1X1 4/20 0.43
▸ DPP9 Q86TI2 4/20 0.43
▸ DPP4 P27487 2/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ PLG P00747 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22163010 1.00 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL362251 1.00 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL24722227 1.00 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL361149 1.00 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL5498760 0.98 GSR (0.67) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL363001 0.98 GSR (0.67) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL358119 0.98 GSR (0.67) GSRGNAI3GNAO1GNAI1CPB2
SCHEMBL29483946 0.98 GSR (0.67) GSRGNAI3GNAO1GNAI1CPB2
Hydrochloric Acid SCHEMBL14831515 0.95 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2
Hydrochloric Acid SCHEMBL8497748 0.95 GSR (0.64) GSRGNAI3GNAO1GNAI1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130171252-A1 Formulation Comprising a Type B Lantibiotic NOVACTA BIOSYSTEMS LIMITED (GB) 2013-07-04 — — US claimed
EP-2627320-A1 FORMULATION COMPRISING A TYPE B LANTIBIOTIC Novacta Biosystems Limited (GB) 2013-08-21 — — EP disclosed
US-20130171252-A1 Formulation Comprising a Type B Lantibiotic NOVACTA BIOSYSTEMS LIMITED (GB) 2013-07-04 — — US disclosed
WO-2012007711-A1 FORMULATION COMPRISING A TYPE B LANTIBIOTIC NOVACTA BIOSYSTEMS LIMITED (GB) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130171252-A1 Formulation Comprising a Type B Lantibiotic CCKBR, GIPR, SI GSR 3108/4885GNAI3 3031/4885GNAO1 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback